Arbutus Biopharma Corp (ABUS): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Arbutus Biopharma Corp (ABUS) following the 2026 Q1 hedge fund 13F filings?

As of today, ABUS has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), ABUS gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Arbutus Biopharma Corp (ABUS)

163 + Investors. Track Smart Money conviction in ABUS. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ABUS

Based on 164 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their ABUS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

📊

High ownership — 94% of 3.0Y peak

94% of all-time peak

164 funds currently hold this stock — 94% of the 3.0-year high of 174 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

📉

Outflows — 4% fewer funds vs a year ago

fund count last 6Q

6 fewer hedge funds hold ABUS compared to a year ago (-4% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🟠

More sellers than buyers — 46% buying

77 buying89 selling

Last quarter: 89 funds reduced or exited vs 77 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

➡️

Steady new buyers — ~28 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 14 → 24 → 23 → 28. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 28% medium ■ 20% new

86 out of 164 hedge funds have held ABUS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

📈

Growing discovery — still being found

30 → 14 → 24 → 23 → 28 new funds/Q

New funds entering each quarter: 14 → 24 → 23 → 28. A growing number of institutions are discovering ABUS each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 56% veterans vs 22% newcomers

■ 56% veterans ■ 22% 1-2yr ■ 22% new

Entry-cohort mix of 171 holders: 96 (56%) are 2+ year veterans, 37 entered 1–2 years ago, and 38 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 40% AUM from top-100 funds

40% from top-100 AUM funds

39 of 162 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in ABUS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.4

out of 10

Low Exit Risk

Exit risk score 3.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	163	174	-6.32%
13F Shares	140M	126M	11.2%
Total Value	$628M	$604M	3.95%
New Positions	28	23	+5
Increased Positions	46	57	-11
Closed Positions	39	20	+19
Reduced Positions	49	44	+5
Total Calls	5	11	-54.55%
Total Puts	4	7	-42.86%
PUT/CALL Ratio	0.8	0.64	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

163

174

-6.32%

13F Shares

140M

126M

11.2%

Total Value

$628M

$604M

3.95%

New Positions

Increased Positions

-11

Closed Positions

+19

Reduced Positions

Total Calls

-54.55%

Total Puts

-42.86%

PUT/CALL Ratio

0.8

0.64

Neutral

Institutional Holders (2026 Q1)

163 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ABUS. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ABUS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Whitefort Capital Management, LP	19.81%	14,930,885	$67.2M
2	Rangeley Capital, LLC	2.19%	500,000	$2.2M
3	Western Standard LLC	1.23%	521,587	$2.3M
4	Two Seas Capital LP	1.17%	18,557,543	$83.5M
5	BlackBarn Capital Partners LP	0.91%	2,500,000	$11.2M
6	ADAR1 Capital Management, LLC	0.83%	3,133,175	$14.1M
7	Ledgewood Wealth Advisors, LLC	0.71%	278,436	$1.3M
8	Deltroit Asset Management (UK) LLP	0.58%	800,000	$3.6M
9	Rubric Capital Management LP	0.32%	6,626,389	$29.8M
10	Wealth Management Associates, Inc.	0.20%	131,870	$593K
11	Exome Asset Management LLC	0.18%	75,484	$340K
12	Carrera Capital Advisors	0.17%	252,159	$1.1M
13	Front Row Advisors LLC	0.17%	110,500	$497K
14	EntryPoint Capital, LLC	0.15%	110,123	$496K
15	Quinn Opportunity Partners LLC	0.12%	514,513	$2.3M
16	Avidity Partners Management LP	0.12%	125,000	$525K
17	Virtus Investment Advisers, LLC	0.07%	57,895	$261K
18	Freestone Capital Holdings, LLC	0.06%	442,500	$2.0M
19	Jefferies Financial Group Inc.	0.06%	1,894,067	$8.5M
20	JBF Capital, Inc.	0.05%	80,281	$361K
21	Kennedy Capital Management LLC	0.04%	393,132	$1.8M
22	Inceptionr LLC	0.04%	32,580	$147K
23	Woodline Partners LP	0.03%	2,010,172	$9.0M
24	Cura Wealth Advisors, LLC	0.03%	15,000	$68K
25	Campbell & CO Investment Adviser LLC	0.03%	103,412	$465K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Arbutus Biopharma Corp (ABUS)

What does the Smart Money Trend signal show for ABUS?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their ABUS positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ABUS?

More sellers than buyers — 46% buying: Last quarter: 89 funds reduced or exited vs 77 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ABUS holders?

Elite ownership — 40% AUM from top-100 funds: 39 of 162 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in ABUS. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ABUS?

52% of holders stayed for 2+ years: 86 out of 164 hedge funds have held ABUS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Arbutus Biopharma Corp (ABUS) following the 2026 Q1 hedge fund 13F filings?

As of today, ABUS has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), ABUS has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Arbutus Biopharma Corp (ABUS)

Smart Money Signals — ABUS

Selling streak — 1 quarter in a row

High ownership — 94% of 3.0Y peak

Outflows — 4% fewer funds vs a year ago

More sellers than buyers — 46% buying

Steady new buyers — ~28 new funds per quarter

52% of holders stayed for 2+ years

Growing discovery — still being found

Veteran-anchored — 56% veterans vs 22% newcomers

Elite ownership — 40% AUM from top-100 funds

Institutional Sentiment Summary — ABUS

Hedge Fund Ownership: ABUS

Market Analysis: ABUS

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ABUS

Is It Too Late to Buy Arbutus Biopharma Corp (ABUS) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ABUS

Statistics: ABUS

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Arbutus Biopharma Corp (ABUS)

Welcome to 13Foresight!